Inhibikase names Kailera CMO Scott Wasserman to board, Berman resigns

Inhibikase Therapeutics said on October 20, 2026 that it had appointed Scott M. Wasserman, MD, to its Board of Directors, effective October 19, 2026.¹ The company also disclosed that Dennis Berman had resigned from the board at the same time.¹ According to the 8-K, Berman resigned from the board and his positions as Chair of the Compensation Committee and a member of the Audit Committee effective October 19, 2026, and he told the company the decision was not the result of any disagreement with the company or its management.¹

Wasserman currently holds an active operating role elsewhere in the industry. He is currently Chief Medical Officer of Kailera Therapeutics, a clinical-stage company developing GLP-1-based therapeutics for obesity and related conditions.¹ He previously spent years at Amgen, where he served as Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience, and was Amgen's first cardiologist, building its cardiovascular and metabolic strategy, team and portfolio.¹ At Amgen, he led the global development and approvals of Repatha (evolocumab), was instrumental in the development and U.S. FDA approval of Evenity (romosozumab), and oversaw the U.S. approval of Aimovig (erenumab).¹

Per the filing, the board appointed Wasserman upon recommendation of its Corporate Governance and Nominating Committee to serve as a Class III director, with a term running until the 2029 annual meeting or his earlier death, resignation or removal.¹ He will also serve as a member of the Compensation Committee.¹ The company said the board determined Wasserman is independent under Nasdaq listing standards and SEC rules.¹

As compensation, Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of common stock, plus cash compensation for board and committee service under the company's director compensation policy.¹

Inhibikase's lead candidate, IKT-001, is a prodrug of imatinib mesylate being developed for Pulmonary Arterial Hypertension, an orphan indication.¹ The company noted its single pivotal Phase 3 study, IMPROVE-PAH, spans approximately 180 sites globally and is actively enrolling patients.¹